First trimester exposure to cefuroxime: a prospective cohort study

被引:10
|
作者
Berkovitch, M [2 ]
Segal-Socher, I
Greenberg, R
Bulkowshtein, M
Arnon, J
Merlob, P
Or-Noy, A
机构
[1] Tel Aviv Univ, Sackler Fac Med, Rabin Med Ctr, Dept Neonatol, Petah Tiqwa, Israel
[2] Assaf Harofeh Med Ctr, Div Paediat, Clin Pharmacol & Toxicol Unit, IL-70300 Zerifin, Israel
[3] Hebrew Univ Jerusalem, Hadassah Med Sch, IL-91010 Jerusalem, Israel
[4] Israeli Minist Hlth, Israeli Teratogen Informat Serv, Jerusalem, Israel
关键词
cefuroxime; pregnancy; teratogenicity;
D O I
10.1046/j.1365-2125.2000.00240.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Aims There are no published studies on the safety of cefuroxime use during pregnancy. We therefore investigated prospectively the possible teratogenic effect of intrauterine exposure to cefuroxime. Methods One hundred and six women who received cefuroxime during the first trimester of pregnancy were recruited from three teratogen information centres in Israel. Exposed women were paired for age, smoking habits and alcohol consumption with references being exposed to nonteratogenic antibiotics administered for the same indications. Results Maternal history, birthweight, gestational age at delivery, rates of live births, spontaneous abortions and fetal distress were comparable among the two groups. Rates of major malformations in the cefuroxime group (3.2%) did not differ from references (2%) (P=0.61, relative risk = 1.56, 95% confidence interval 0.27-9.15). There was a significantly higher rate of induced abortions among the cefuroxime exposed women as compared to the references (P=0.04, relative risk = 3.33, 95% confidence interval 0.94-11.77). Conclusions Our data may suggest that exposure to cefuroxime during the first trimester is probably not associated with an increased risk for malformations or spontaneous abortions; however, in light of the small sample size and the broad confidence limits, larger studies are needed to confirm these findings.
引用
收藏
页码:161 / 165
页数:5
相关论文
共 50 条
  • [1] Safety of first-trimester exposure to topical tretinoin: prospective cohort study
    Shapiro, L
    Pastuszak, A
    Curto, G
    Koren, G
    LANCET, 1997, 350 (9085): : 1143 - 1144
  • [2] Pregnancy outcome after first-trimester exposure to metformin: A prospective cohort study
    Scherneck, Stephan
    Schlinke, Natalie
    Beck, Evelin
    Grupe, Katharina
    Weber-Schoendorfer, Corinna
    Schaefer, Christof
    REPRODUCTIVE TOXICOLOGY, 2018, 81 : 79 - 83
  • [3] Prospective Cohort Study of Pregnancy Outcome Following First-Trimester Exposure to Propofol
    Cournot, M. P.
    Vauzelle-Gardier, C.
    Beghin, D.
    Elefant, E.
    DRUG SAFETY, 2009, 32 (10) : 977 - 978
  • [4] First trimester exposure to flubendazole: a prospective comparative study
    Garayt, C.
    Carlier, P.
    Logerot, S.
    Beyens, M. N.
    Bernard, N.
    Gouraud, A.
    Vial, T.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2009, 23 : 94 - 94
  • [5] First trimester exposure to tramadol: a prospective comparative study
    Gouraud, A.
    Beyens, M. N.
    Boyer, M.
    Carlier, P.
    Thompson, M. A.
    Garayt, C.
    Bernard, N.
    Vial, T.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2010, 24 : 90 - 90
  • [6] First trimester exposure to domperidone: a comparative prospective study
    Cottin, J.
    Beghin, D.
    Jonville-Bera, A. P.
    Boyer, M.
    Zenut, M.
    Damase-Michel, C.
    Elefant, E.
    Descotes, J.
    Vial, T.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2013, 27 : 44 - 44
  • [7] Pregnancy outcome following first-trimester exposure to zopiclone: A prospective controlled cohort study
    Diav-Citrin, O
    Okotore, B
    Lucarelli, K
    Koren, G
    AMERICAN JOURNAL OF PERINATOLOGY, 1999, 16 (04) : 157 - 160
  • [8] Safety of first trimester exposure to histamine H-2 blockers - A prospective cohort study
    Magee, LA
    Inocencion, G
    Kamboj, L
    Rosetti, F
    Koren, G
    DIGESTIVE DISEASES AND SCIENCES, 1996, 41 (06) : 1145 - 1149
  • [9] Assessment of the Safety of Exposure to Cefcapene Pivoxil during the First Trimester of Pregnancy: A Prospective Cohort Study in Japan
    Miki, Yosuke
    Koga, Yuki
    Taogoshi, Takanori
    Itamura, Ryo
    Yokooji, Tomoharu
    Hishinuma, Kayoko
    Yakuwa, Naho
    Goto, Mikako
    Murashima, Atsuko
    Matsuo, Hiroaki
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2024, 47 (07) : 1301 - 1306
  • [10] Risks of miscarriage and inadvertent exposure to artemisinin derivatives in the first trimester of pregnancy: a prospective cohort study in western Kenya
    Dellicour, Stephanie
    Desai, Meghna
    Aol, George
    Oneko, Martina
    Ouma, Peter
    Bigogo, Godfrey
    Burton, Deron C.
    Breiman, Robert F.
    Hamel, Mary J.
    Slutsker, Laurence
    Feikin, Daniel
    Kariuki, Simon
    Odhiambo, Frank
    Pandit, Jayesh
    Laserson, Kayla F.
    Calip, Greg
    Stergachis, Andy
    ter Kuile, Feiko O.
    MALARIA JOURNAL, 2015, 14